Compare Kroger Co (KR) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Organon & Co. Common Stock — how do they compare? Kroger Co trades at $63.88 (market cap $35.87B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Kroger Co is far larger — about 9.9× Organon & Co. Common Stock's market cap, and Kroger Co pays the higher dividend (2.57%). Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 109 Days and Organon & Co. Common Stock for 0 Days on average.
| KR | OGN | |
|---|---|---|
Market Cap | $35.87B | $3.62B |
Volume | 8,902,665 | 2,892,999 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $13.81 |
52-Week Low | $55.53 | $5.70 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $57.29B | $11.04B |
Dividend Yield | 2.57% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $63.09, up 0.85% today, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with a low P/S of 0.26 and positive cash flow trends, though net income margin is thin at 0.73%. Recent news highlights digital growth and a strategic shift toward everyday low prices, while earnings have mostly beaten expectations.
Outlook is cautiously optimistic with a $70.62 consensus price target, but risks include integration challenges from acquisitions and cost pressures. The stock offers value with a dividend yield, yet investors should weigh slower sales guidance against operational improvements for near-term performance.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
